These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25537444)

  • 1. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
    Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
    Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
    Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM
    Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment.
    Kim JY; Jung HH; Ahn S; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Sci Rep; 2016 Aug; 6():31804. PubMed ID: 27545642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of triple-negative breast cancer radiosensitive gene signature and validation based on transcriptome analysis.
    Wushou A; Jiang YZ; Hou J; Liu YR; Guo XM; Shao ZM
    Breast Cancer Res Treat; 2015 Nov; 154(1):57-62. PubMed ID: 26476726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
    Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
    Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
    Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
    Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
    Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
    Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.
    Gámez-Pozo A; Trilla-Fuertes L; Prado-Vázquez G; Chiva C; López-Vacas R; Nanni P; Berges-Soria J; Grossmann J; Díaz-Almirón M; Ciruelos E; Sabidó E; Espinosa E; Fresno Vara JÁ
    PLoS One; 2017; 12(6):e0178296. PubMed ID: 28594844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
    Kim JY; Jung HH; Do IG; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Park YH; Im YH
    BMC Cancer; 2016 Feb; 16():138. PubMed ID: 26907936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.
    Liu NQ; Stingl C; Look MP; Smid M; Braakman RB; De Marchi T; Sieuwerts AM; Span PN; Sweep FC; Linderholm BK; Mangia A; Paradiso A; Dirix LY; Van Laere SJ; Luider TM; Martens JW; Foekens JA; Umar A
    J Natl Cancer Inst; 2014 Feb; 106(2):djt376. PubMed ID: 24399849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
    Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
    Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
    Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.